US/UK/Canada

Share

About Us

Maxim Parmaceuticals develops new methods for treatment of cancer and infection diseases

Pick a time period -
Tags ( Active)

Maxim Reports that Additional Phase 3 trial of Ceplene™ therapy in the treatment of acute myeloid leukemia patients in complete remission will be required by the fda

Company Continuing Discussions with European Regulators Regarding AML Application SAN DIEGO, Calif., January 18, 2005 -- Maxim Pharmaceuticals, Inc. (NASDAQ: MAXM, SSE: MAXM) today announced that based on ongoing correspondence with the United States Food and Drug Administration (FDA), as well as consultations with external advisors, an additional Phase 3 clinical trial will be necessary to further evaluate Ceplene plus Interleukin-2 (IL-2) combination therapy for the treatment of acute myeloid leukemia (AML) patients in complete remission before applying for regulatory approval in the

MAXIM PHARMACEUTICALS REPORTS FISCAL 2004 FINANCIAL RESULTS

SAN DIEGO, Calif., December 13, 2004 -- Maxim Pharmaceuticals, Inc. (NASDAQ NM: MAXM, SSE: MAXM) today reported financial results for the fourth quarter and the year ended September 30, 2004. The net loss applicable to common stock for the fourth quarter ended September 30, 2004 totaled $14.5 million, or $0.51 per share, compared to a net loss applicable to common stock of $12.8 million, or $0.54 per share, for the same period of the prior year. The net loss applicable to common stock for the year ended September 30, 2004, totaled $45.0 million, or $1.59 per share compared to a net loss

MYRIAD GENETICS FILES IND FOR DRUG CANDIDATE FROM COMPOUND FAMILY LICENSED FROM MAXIM PHARMACEUITICALS

SAN DIEGO, Calif., December 9, 2004 -- Maxim Pharmaceuticals, Inc. (NASDAQ: MAXM, SSE: MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND) application with the FDA for a Phase 1 clinical study of MPC-6827, a pro-apoptotic cancer therapeutic candidate identified by Myriad researchers from a family of compounds licensed from Maxim. The study is designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors in an escalating dose regimen. This compound family was discovered by Maxim through its proprietary live

Maxim Pharmaceuticals Reports Data from its Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Patients at American Society of Hematology Annual Meeting

SAN DIEGO, December 6, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today additional data from its randomized and controlled Phase 3 trial (MP-MA-0201) investigating Ceplene plus Interleukin-2 (IL-2) in the treatment of acute myeloid leukemia (AML) patients in complete remission during an oral presentation at the American Society of Hematology 46th Annual Meeting and Exposition. The data presented included the updated p-value (p=0.0096) for the primary endpoint of leukemia free survival, and details of the demographics, risk factors and other baseline characteristics of

Maxim's Senior Director of Regulatory Affairs and Drug Safety Resigns

John Bedard to Act as Interim Head of Regulatory Affairs SAN DIEGO, December 6, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today that Richard Lowenthal, Senior Director of Regulatory Affairs and Drug Safety at Maxim, has resigned to pursue an opportunity to be one of the first employees of an early-stage biotechnology company. Sharon Tonetta, Ph.D., Vice President of Drug Development, and Mr. Lowenthal’s supervisor at Maxim, will continue to head the company’s regulatory affairs and drug safety. Additionally, John F. Bedard, a member of Maxim’s board of directors, has

MAXIM PHARMACEUTICALS TO HOST CONFERENCE CALL

- Review of AML Data Presented at ASH to be Provided -SAN DIEGO, December 2, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced it will hold a conference call on Tuesday, December 7, 2004 at 10:00 a.m. EST (7:00 a.m. PST or 4:00 p.m. CET). Larry Stambaugh, Chairman and Chief Executive Officer of Maxim, will discuss the results of Maxim’s Phase 3 clinical trial for Ceplene™ in the treatment of acute myeloid leukemia patients in complete remission as presented on December 6, 2004 at the 46th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA. To

Maxim Pharmaceuticals Announces Publication of Two Manuscripts Describing Pre-Clinical Anticancer Ac

SAN DIEGO, December 1, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics (Mol Cancer Ther 2004 3: pp. 1365-1374 and 1375-1384) describing Maxim’s MX116407 anticancer drug candidate as part of a novel class of microtubule inhibitors with vascular targeting activity. The manuscripts characterize MX116407 as a potent caspase activator with strong antitumor activity in pre-clinical in vitro and in vivo studies. MX116407 appeared highly effective in mouse tumor models, producing tumor

Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma

Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma Results of Phase 3 Clinical Trial for Advanced Malignant Melanoma Presented at 29th ESMO Congress SAN DIEGO, November 1, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene® (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA

Maxim Pharmaceuticals to Present at Rodman & Renshaw Conference

Maxim Pharmaceuticals to Present at Rodman & Renshaw Conference SAN DIEGO, October 22, 2004 -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on Tuesday, October 26, 2004 at 11:30 am Eastern Time in the Waldorf Astoria Hotel. Larry Stambaugh, Maxim's Chief Executive Officer, will present an overview of the Company's business operations and clinical development. A live webcast of the presentation will be available at http://www.maxim.com. Please log onto the website several minutes prior to

MAXIM PHARMACEUTICALS APPOINTS JOHN F. BEDARD TO BOARD OF DIRECTORS

MAXIM PHARMACEUTICALS APPOINTS JOHN F. BEDARD TO BOARD OF DIRECTORS SAN DIEGO, October 5, 2004 -- Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today that John F. Bedard, 55, was appointed to the Company's board of directors. Mr. Bedard will serve as the seventh independent outside director on the eight person board. With over twenty-five years of experience directing drug development and registration programs in the pharmaceutical industry, Mr. Bedard brings valuable experience to Maxim. Since 2002 Mr. Bedard has been engaged as a principal in a pharmaceutical consulting

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS OF NOVEL CANCER COMPOUND DISCOVERED BY ITS RESEARCH TEAM AT THE AACR-

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS OF NOVEL CANCER COMPOUND DISCOVERED BY ITS RESEARCH TEAM AT THE AACR-EORTC Preclinical Studies Suggest Previously Unknown Apoptotic Role of Transferrin Receptor SAN DIEGO, October 1, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) reported earlier this week at the AACR-EORTC-NCI International Conference "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland, that MX2167, a novel anticancer agent discovered by its research team and under development, targets the transferrin receptor leading to a previously unknown rapid

MAXIM PHARMACEUTICAL PHASE 3 TRIAL FOR ADVANCED MALIGNANT MELANOMA FAILS TO MEET PRIMARY ENDPOINT

MAXIM PHARMACEUTICAL PHASE 3 TRIAL FOR ADVANCED MALIGNANT MELANOMA FAILS TO MEET PRIMARY ENDPOINT CONFERENCE CALL SCHEDULED FOR SEPTEMBER 20, 2004, 7:30 AM PACIFIC TIME SAN DIEGO, September 20, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced that its confirmatory Phase 3 trial (M104) of the investigational drug Ceplene® (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) for the treatment of advanced malignant melanoma patients with liver metastases failed to demonstrate an improvement in overall patient survival, the primary endpoint. The

MAXIM PHARMACEUTICALS ANNOUNCES 2004 THIRD QUARTER FINANCIAL RESULTS

MAXIM PHARMACEUTICALS ANNOUNCES 2004 THIRD QUARTER FINANCIAL RESULTS SAN DIEGO, Calif., August 3, 2004 -- Maxim Pharmaceuticals, Inc. (Nasdaq NM: MAXM, SSE: MAXM) today announced results for the quarter ended June 30, 2004, the third quarter of its 2004 fiscal year. The net loss for the quarter totaled $11.7 million, or $0.41 per share, compared to a net loss of $12.4 million, or $0.53 per share, for the prior-year third quarter. For the nine months ended June 30, 2004, the net loss totaled $30.5 million or $1.08 per share, compared to a net loss of $32.7 million or $1.40 per share for the

MAXIM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RICHARD A. MAFRICA AS VICE PRESIDENT COMMERCIALIZATION

MAXIM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF RICHARD A. MAFRICA AS VICE PRESIDENT COMMERCIALIZATION SAN DIEGO, July 27, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced the appointment of Richard A. Mafrica, 47, to the newly created position of Vice President Commercialization. Mr. Mafrica joins Maxim with over twenty years of healthcare related sales and marketing experience including a fourteen-year tenure with Amgen, Inc. Most recently Mr. Mafrica served as the Senior Director, Oncology Sales and Marketing, playing a key role in Amgens' commercial oncology

MAXIM PHARMACEUTICALS ADDED TO RUSSELL 2000 INDEX

MAXIM PHARMACEUTICALS ADDED TO RUSSELL 2000 INDEX SAN DIEGO, June 29, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced that its stock has been added to the Russell 2000 Index. The annual reconstitution of Russell's 21 U.S. equity indexes captures the 3,000 largest U.S. stocks, ranking them by market capitalization to create the broad market Russell 3000 Index. The largest 1,000 companies in the ranking will comprise the large-cap Russell 1000 Index while the remaining 2,000 companies will comprise the small-cap Russell 2000 Index. Russell indexes are now used as a model for

MAXIM PHARMACEUTICALS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

Contacts: Larry G. Stambaugh Aline Schimmel (Investors) Chief Executive Officer Burns McClellan Anthony E. Altig (212) 213-0006 Chief Financial Officer Sean Collins (Media) (858) 453-4040 Valerie Bent (Media) CCG Investor Relations (818) 789-0100 MAXIM PHARMACEUTICALS ADDED TO NASDAQ BIOTECHNOLOGY INDEX SAN DIEGO, May 25, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced that it has been added to the NASDAQ Biotechnology Index® (NBI). All securities in the Index are listed on the NASDAQ National Market and meet minimum requirements including market value, average daily

MAXIM PHARMACEUTICALS ANNOUNCES FINAL DISMISSAL OF FEDERAL LAWSUIT

MAXIM PHARMACEUTICALS ANNOUNCES FINAL DISMISSAL OF FEDERAL LAWSUIT SAN DIEGO-- (BUSINESS WIRE)- May 20, 2004--Maxim Pharmaceuticals, Inc. (Nasdaq NM: MAXM)(SSE: MAXM) announced that the Plaintiff in the Company's federal class action securities complaint has dropped their appeal of the court's previous dismissal of the action, ending the litigation. On December 14, 2000, the plaintiff Blake Martin, on behalf of himself and purportedly on behalf of a class of similarly situated stockholders, filed a complaint in the United States District Court for the Southern District of California against

MAXIM PHARMACEUTICALS PRESENTS NEW PRECLINICAL RESULTS SHOWING PREVENTION OF LIVER INJURY BY HISTAMINE

MAXIM PHARMACEUTICALS PRESENTS NEW PRECLINICAL RESULTS SHOWING PREVENTION OF LIVER INJURY BY HISTAMINE Data presented as a poster-of-distinction at Digestive Disease Week in New Orleans SAN DIEGO, May 18, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced preclinical results demonstrating the ability of histamine to prevent lipopolysaccharide (LPS)-induced liver injury in a rodent model. In this model, presented as a liver disease poster-of- distinction at the annual Digestive Disease Week (DDW) meeting in New Orleans, the addition of histamine reduced pro-inflammatory

MAXIM PHARMACEUTICALS ANNOUNCES PHASE 3 TRIAL OF CEPLENE(TM) IN ACUTE MYELOID LEUKEMIA MEETS PRIMARY TRIAL ENDPOINT

Contacts: Larry G. Stambaugh Aline Schimmel (Investors) Chief Executive Officer Burns McClellan Anthony E. Altig (212) 213-0006 Chief Financial Officer Sean Collins (Media) (858) 453-4040 Valerie Bent (Media) CG Investor Relations 18) 789-0100 MAXIM PHARMACEUTICALS ANNOUNCES PHASE 3 TRIAL OF CEPLENE(TM) IN ACUTE MYELOID LEUKEMIA MEETS PRIMARY TRIAL ENDPOINT Ceplene Treatment Significantly Improves Leukemia-Free Survival in AML Patients SAN DIEGO, May 12, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced the results of an international Phase 3 clinical trial testing the

MAXIM PHARMACEUTICALS ANNOUNCES 2004 SECOND QUARTER FINANCIAL RESULTS

MAXIM PHARMACEUTICALS ANNOUNCES 2004 SECOND QUARTER FINANCIAL RESULTS SAN DIEGO, Calif., May 4, 2004 -- Maxim Pharmaceuticals, Inc. (Nasdaq NM: MAXM, SSE: MAXM) today announced results for the quarter ended March 31, 2004, the second quarter of its fiscal year. The net loss applicable to common stock for the quarter totaled $8.9 million, or $0.32 per share, compared to a loss applicable to common stock of $11.0 million, or $0.47 per share, for the prior-year quarter. The net loss applicable to common stock for the six months ended March 31, 2004, totaled $18.8 million or $0.67 per share,

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON HISTAMINE´S ABILITY TO PREVENT LIVER DAMAGE

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON HISTAMINE'S ABILITY TO PREVENT LIVER DAMAGE Results presented at the European Association for the Study of the Liver (EASL) SAN DIEGO, April 19, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced preclinical results indicating that histamine may prevent lipopolysaccharide (LPS)-induced liver injury. The results were presented at the 39th annual European Association for the Study of the Liver (EASL) meeting in Berlin, Germany. In this preclinical study, LPS is used to increase the severity of alcohol-induced damage. These new

MAXIM PHARMACEUTICALS RECEIVES APPROVAL FROM FDA OF A TREATMENT PROTOCOL FOR CEPLENE (TM) IN ADVANCED MALIGNANT MELANOM

MAXIM PHARMACEUTICALS RECEIVES APPROVAL FROM FDA OF A TREATMENT PROTOCOL FOR CEPLENE(TM) IN ADVANCED MALIGNANT MELANOMA Webcast scheduled for April 14, 2004, 10:30 AM Eastern time to discuss details SAN DIEGO, April 14, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL- 2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA). The treatment protocol allows Maxim to provide expanded

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS FOR ITS NOVEL VASCULAR TARGETING AGENT MX116407

MAXIM PHARMACEUTICALS PRESENTS PRECLINICAL RESULTS FOR ITS NOVEL VASCULAR TARGETING AGENT MX116407 Results for MX116407 and MX90745 presented at American Association for Cancer Research Annual Meeting San Diego, California, March 30, 2004 - Maxim Pharmaceuticals (Nasdaq NM: MAXM, SSE: MAXM) today announced research results demonstrating the anti-cancer activity of the Company's MX116407 compounds at the 2004 American Association of Cancer Research (AACR) meeting in Orlando, Florida. Maxim scientists presented key results demonstrating that treatment with MX116407 as a single agent produced

There are no items matching the current filter
There are no more items matching the current filter
Back to top